Results 31 to 40 of about 37,664 (239)
Proteogenomic characterization of cholangiocarcinoma
Hepatology, EarlyView., 2022 Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng +18 more
wiley +1 more source
生物医学转化, 2021 Apert syndrome (AS) is characterized by synostosis of coronal sutures, midfacial hypoplasia,abnormity of brain, syndactyly of hands and feet. Majority of AS is caused by gain-of-function mutation of fibro‐blast growth factor receptor 2 (FGFR2).
Luo Fengtao +5 more
doaj +1 more source
Cancer Treatment and Research Communications, 2022 According to previous reports,10-16% of patients with clinically advanced cholangiocarcinoma develop FGFR2 fusions or rearrangements. Treatment with FGFR2-specific inhibitors (tyrosine kinase inhibitors, TKIs) has proven effective for patients with cholangiocarcinoma.
Chunye Huang +6 more
openaire +3 more sources
FGFR2 signaling and the pathogenesis of acne [PDF]
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2008 SummaryAcne in Apert syndrome and unilateral segmental acneiform nevus are associated with mutations of fibroblast growth factor receptor 2 (FGFR2), which are likely to be involved in the pathogenesis of acne. Translational animal and cellular models, developmental biology studies and clinical observations have contributed to our understanding of FGF ...
Bodo, Melnik, Gerd, Schmitz
openaire +2 more sources
FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma
Journal of Translational Medicine, 2021 Background Poorly cohesive (PC) is a unique histologic subtype of gastric cancer (GC), with an increasing incidence in recent years. However, the molecular characteristics and therapeutic targets of PC GC are not yet well studied and there are no ...
Yue Wang +8 more
doaj +1 more source
Biochimica et Biophysica Acta - Molecular Basis of Disease, 2023 Fibroblast growth factor receptor 2 (FGFR2) is frequently activated by overexpression or mutation, and an abnormal fibroblast growth factor (FGF)/FGFR signaling pathway is associated with the occurrence, development, and poor prognosis of colorectal ...
Yiming Li +9 more
semanticscholar +1 more source
FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice
Pathologica, 2023 Summary Cholangiocarcinoma (CCA) is a heterogeneous group of neoplasms burdened by a dismal prognosis. Several studies have investigated the genomic profile of CCA and identified numerous druggable genetic alterations, including FGFR2 fusions ...
Valentina Angerilli +6 more
semanticscholar +1 more source
Clinical and Experimental Hypertension, 2023 Background Fibroblast growth factor receptor (FGFR)2 expression was decreased in hypertension patients while its role in hypertension was not explored. This experiment aimed to investigate the expression ofFGFR2 in angiotensin II (Ang II)-induced human ...
Kun Jiao, Ping Su, Yongling Li
doaj +1 more source
Clinical and Translational Medicine, 2023 Background Mutations in the receptor tyrosine kinase gene fibroblast growth factor receptor 2 (FGFR2) occur at a high frequency in endometrial cancer (EC) and have been linked to advanced and recurrent disease.
G. Dixit +8 more
semanticscholar +1 more source
Frontiers in Immunology, 2023 Introduction Lung metastasis occurs in parts of the bladder carcinoma (BC) patients but represents the highest severity and a poor outcome of the disease. The molecular mechanism underlying lung metastasis of BC is not fully understood. Fibroblast growth
Yuyang Zhao +4 more
semanticscholar +1 more source